727 related articles for article (PubMed ID: 28072416)
1. Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration.
Höglund K; Kern S; Zettergren A; Börjesson-Hansson A; Zetterberg H; Skoog I; Blennow K
Transl Psychiatry; 2017 Jan; 7(1):e995. PubMed ID: 28072416
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
[TBL] [Abstract][Full Text] [Related]
3. Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus.
Lukkarinen H; Tesseur I; Pemberton D; Van Der Ark P; Timmers M; Slemmon R; Janssens L; Streffer J; Van Nueten L; Bottelbergs A; Rauramaa T; Koivisto AM; Herukka SK; Korhonen VE; Junkkari A; Hiltunen M; Engelborghs S; Blennow K; Zetterberg H; Kolb HC; Leinonen V
J Alzheimers Dis; 2021; 80(4):1629-1642. PubMed ID: 33720890
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.
Tarawneh R; D'Angelo G; Crimmins D; Herries E; Griest T; Fagan AM; Zipfel GJ; Ladenson JH; Morris JC; Holtzman DM
JAMA Neurol; 2016 May; 73(5):561-71. PubMed ID: 27018940
[TBL] [Abstract][Full Text] [Related]
5. A Non-APOE Polygenic Risk Score for Alzheimer's Disease Is Associated With Cerebrospinal Fluid Neurofilament Light in a Representative Sample of Cognitively Unimpaired 70-Year Olds.
Skoog I; Kern S; Najar J; Guerreiro R; Bras J; Waern M; Zetterberg H; Blennow K; Zettergren A
J Gerontol A Biol Sci Med Sci; 2021 May; 76(6):983-990. PubMed ID: 33512503
[TBL] [Abstract][Full Text] [Related]
6. Poor sleep is associated with CSF biomarkers of amyloid pathology in cognitively normal adults.
Sprecher KE; Koscik RL; Carlsson CM; Zetterberg H; Blennow K; Okonkwo OC; Sager MA; Asthana S; Johnson SC; Benca RM; Bendlin BB
Neurology; 2017 Aug; 89(5):445-453. PubMed ID: 28679595
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM
JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
9. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
10. Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ
Hampel H; Toschi N; Baldacci F; Zetterberg H; Blennow K; Kilimann I; Teipel SJ; Cavedo E; Melo Dos Santos A; Epelbaum S; Lamari F; Genthon R; Dubois B; Floris R; Garaci F; Lista S;
Alzheimers Dement; 2018 Apr; 14(4):492-501. PubMed ID: 29328927
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum.
Bos I; Vos S; Verhey F; Scheltens P; Teunissen C; Engelborghs S; Sleegers K; Frisoni G; Blin O; Richardson JC; Bordet R; Tsolaki M; Popp J; Peyratout G; Martinez-Lage P; Tainta M; Lleó A; Johannsen P; Freund-Levi Y; Frölich L; Vandenberghe R; Westwood S; Dobricic V; Barkhof F; Legido-Quigley C; Bertram L; Lovestone S; Streffer J; Andreasson U; Blennow K; Zetterberg H; Visser PJ
Alzheimers Dement; 2019 May; 15(5):644-654. PubMed ID: 30853464
[TBL] [Abstract][Full Text] [Related]
12. Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease.
Alcolea D; Martínez-Lage P; Sánchez-Juan P; Olazarán J; Antúnez C; Izagirre A; Ecay-Torres M; Estanga A; Clerigué M; Guisasola MC; Sánchez Ruiz D; Marín Muñoz J; Calero M; Blesa R; Clarimón J; Carmona-Iragui M; Morenas-Rodríguez E; Rodríguez-Rodríguez E; Vázquez Higuera JL; Fortea J; Lleó A
Neurology; 2015 Aug; 85(7):626-33. PubMed ID: 26180139
[TBL] [Abstract][Full Text] [Related]
13. Biomarker profiling beyond amyloid and tau: cerebrospinal fluid markers, hippocampal atrophy, and memory change in cognitively unimpaired older adults.
Idland AV; Sala-Llonch R; Watne LO; Brækhus A; Hansson O; Blennow K; Zetterberg H; Sørensen Ø; Walhovd KB; Wyller TB; Fjell AM
Neurobiol Aging; 2020 Sep; 93():1-15. PubMed ID: 32438258
[TBL] [Abstract][Full Text] [Related]
14. Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults.
Dayon L; Wojcik J; Núñez Galindo A; Corthésy J; Cominetti O; Oikonomidi A; Henry H; Migliavacca E; Bowman GL; Popp J
J Alzheimers Dis; 2017; 60(4):1641-1652. PubMed ID: 29125490
[TBL] [Abstract][Full Text] [Related]
15. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease.
Hellwig K; Kvartsberg H; Portelius E; Andreasson U; Oberstein TJ; Lewczuk P; Blennow K; Kornhuber J; Maler JM; Zetterberg H; Spitzer P
Alzheimers Res Ther; 2015 Dec; 7():74. PubMed ID: 26698298
[TBL] [Abstract][Full Text] [Related]
16. Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40.
Deming Y; Black K; Carrell D; Cai Y; Del-Aguila JL; Fernandez MV; Budde J; Ma S; Saef B; Howells B; Bertelsen S; Huang KL; Sutphen CL; Tarawneh R; Fagan AM; Holtzman DM; Morris JC; Goate AM; Dougherty JD; Cruchaga C
BMC Neurol; 2016 Nov; 16(1):217. PubMed ID: 27832767
[TBL] [Abstract][Full Text] [Related]
17. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
[TBL] [Abstract][Full Text] [Related]
18. The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease.
Yassine HN; Rawat V; Mack WJ; Quinn JF; Yurko-Mauro K; Bailey-Hall E; Aisen PS; Chui HC; Schneider LS
Alzheimers Res Ther; 2016 Jun; 8():25. PubMed ID: 27358067
[TBL] [Abstract][Full Text] [Related]
19. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
[TBL] [Abstract][Full Text] [Related]
20. CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration.
Alcolea D; Vilaplana E; Suárez-Calvet M; Illán-Gala I; Blesa R; Clarimón J; Lladó A; Sánchez-Valle R; Molinuevo JL; García-Ribas G; Compta Y; Martí MJ; Piñol-Ripoll G; Amer-Ferrer G; Noguera A; García-Martín A; Fortea J; Lleó A
Neurology; 2017 Jul; 89(2):178-188. PubMed ID: 28592456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
